Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAGM.L Regulatory News (AGM)

  • There is currently no data for AGM

AGM Statement

18 Dec 2018 07:00

RNS Number : 7418K
Applied Graphene Materials PLC
18 December 2018
 

18 December 2018

 

Applied Graphene Materials plc

 

("Applied Graphene Materials", "the Group" or "the Company")

 

Annual General Meeting Statement

 

Key milestone achieved with James Briggs Ltd order

 

Applied Graphene Materials, the producer of specialty graphene materials, will be holding its Annual General Meeting at 11.00am today at The Farndale Suite, The Wilton Centre, Redcar, Cleveland, TS10 4RF, during which the Chairman, Bryan Dobson, will make the following statement: 

"The Board continues to focus on the commercialisation of its products and proprietary technologies via its numerous active engagements and has made good progress in recent months.

I am pleased to report that we have recently achieved a key milestone, having fulfilled the scale-up production purchase order from James Briggs Ltd (JBL) in preparation for full product launch. JBL has successfully completed its first production batch which is a significant milestone for commercial realisation. Extensive testing has demonstrated repeated and outstanding improvements in anti-corrosion performance for JBL's automotive aerosol primer. JBL plans to launch their new range of graphene enhanced anti-corrosion aerosols under their Hycote brand.

We were also pleased to participate in the opening of the UK's Graphene Engineering and Innovation Centre (GEIC) in Manchester last week. Meeting with multiple participants, the opportunities for graphene technology remain buoyant. Finding practical application solutions for the challenges surrounding the exploitation of graphene nanoplatelet technology is the key focus of AGM's strategy for commercial progress and this is wholly complementary to the objectives of GEIC. We look forward to working closely with GEIC in the months ahead in the further development of world-class application solutions. 

We have had significant changes on the Executive team in the last few months and Adrian and David have both settled into their new roles very quickly as Chief Executive and Chief Financial Officer. Their absolute focus is to increase the commercial momentum and to grow the business and revenues.

The Group continues to be well funded as it seeks to capitalise on the ever maturing pipeline of opportunities."

 

For further information, please contact:

 

Applied Graphene Materials +44 (0) 1642 438 214

Adrian Potts, Chief Executive Officer

David Blain, Chief Financial Officer

 

N+1 Singer +44 (0) 207 496 3000

Richard Lindley / Justin McKeegan

 

Hudson Sandler +44 (0) 207 796 4133

Charlie Jack / Emily Dillon

Notes to Editors

Applied Graphene Materials works in partnership with its customers using its knowledge and expertise to provide bespoke graphene dispersions and formats to deliver enhancements and benefits for a wide range of applications. The Group's strategy is to target commercial applications in three core markets: coatings, composites and functional materials. 

The Group has developed proprietary bottom-up processes which are capable of producing high purity graphene nanoplatelets using a continuous process. The manufacturing process is based on sustainable, readily available raw materials and therefore does not rely on the supply of graphite, unlike a number of other graphene production techniques. Applied Graphene Materials owns the intellectual property and know-how behind this process.

Applied Graphene Materials was founded by Professor Karl Coleman in 2010 with its operations and processes based on technology that he initially developed at Durham University. The Group was admitted to AIM in November 2013, raising £11 million, and is based at the Wilton Site on Teesside. In January 2016 the Group raised £8.5m to support its ongoing activities and in October 2017 the Group raised a further £9.8m.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMEAKAXFSKPFFF
Date   Source Headline
11th Jan 20163:36 pmRNSDirector/PDMR Shareholding
8th Jan 201612:13 pmRNSResult of Meeting
18th Dec 20157:00 amRNSPlacing and Open Offer
16th Nov 20157:00 amRNSFull Year Results
23rd Oct 20157:00 amRNSJoint Development Agreements and Collaborations
21st Sep 20155:19 pmRNSHolding(s) in Company
18th Sep 20157:00 amRNSPeriod end trading update
9th Jul 20157:00 amRNSIssue of share options to Directors
30th Jun 20153:36 pmRNSHolding(s) in Company
17th Jun 20157:00 amRNSFirst Patent Approval
19th May 20154:40 pmRNSSecond Price Monitoring Extn
19th May 20154:35 pmRNSPrice Monitoring Extension
14th May 20157:00 amRNSPositive results from independent oil trials
27th Apr 20159:21 amRNSHolding(s) in Company
22nd Apr 20154:44 pmRNSHolding(s) in Company
22nd Apr 20153:28 pmRNSHolding(s) in Company
21st Apr 20154:46 pmRNSHolding(s) in Company
17th Apr 20157:00 amRNSPositive results from independent coatings trials
2nd Apr 20159:46 amRNSHolding(s) in Company
1st Apr 20154:39 pmRNSHolding(s) in Company
25th Mar 20157:00 amRNSInterim Results
3rd Feb 20157:00 amRNSTrading Update
27th Jan 201511:25 amRNSIssue of equity and total voting rights
22nd Jan 20157:00 amRNSSenior Management Appointments
22nd Dec 20147:00 amRNSDirectorate Change
15th Dec 201411:36 amRNSResult of AGM
15th Dec 20147:00 amRNSAGM Statement
24th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
17th Nov 20147:00 amRNSInvestor site visit
5th Nov 20147:00 amRNSAppointment of Non-Executive Director
5th Nov 20147:00 amRNSFull Year Results
5th Sep 20147:00 amRNSPre-close update
28th Jul 20147:00 amRNSIssue of share options to Directors
9th Jul 201410:17 amRNSGrant of Options to Directors
2nd Jul 20144:36 pmRNSHolding(s) in Company
23rd May 20143:08 pmRNSIssue of Share Options
30th Apr 20143:40 pmRNSReplacement - Holding(s) in Company
28th Apr 20148:50 amRNSHolding(s) in Company
1st Apr 20147:00 amRNSAppointment of Non Executive Director
1st Apr 20147:00 amRNSInterim Results
19th Mar 20147:00 amRNSNotice of Interim Results
18th Mar 201411:00 amRNSDirectorate Change
20th Jan 20144:39 pmRNSHolding(s) in Company
15th Jan 201410:59 amRNSIssue of Equity
27th Nov 20134:40 pmRNSSecond Price Monitoring Extn
27th Nov 20134:35 pmRNSPrice Monitoring Extension
26th Nov 20134:40 pmRNSSecond Price Monitoring Extn
26th Nov 20134:35 pmRNSPrice Monitoring Extension
22nd Nov 201312:39 pmRNSHolding(s) in Company
20th Nov 20137:00 amRNSAdmission and First Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.